Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes

Scientia Pharmaceutica

Volumn 78, Issue 3, 2010, Pages 473-481

  Ho, Beatrice E ^a   Shen, Danny D ^a,b   McCune, Jeannine S ^a,b   Bui, Tot ^a   Risler, Linda ^b   Yang, Ziping ^a   Ho, Rodney J Y ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cytochrome P450 2C9; Drug interactions; Garlic

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GARLIC EXTRACT;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME REPRESSION; GARLIC; GENE REPRESSION; HUMAN; HUMAN CELL; LIVER CELL; PROTEIN EXPRESSION; RNA TRANSCRIPTION;

EID: 77957372879     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1002-11     Document Type: Article

References (21)

1. Bianchini F, Vainio H. Allium vegetables and organosulfur compounds: do they help prevent cancer? Environ Health Perspect. 2001; 109: 893-902. doi:10.2307/3454989
2. Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr. 2001; 131: 1032S-1040S. PMid:11238811
3. White E, Patterson RE, Kristal A R, Thornquist M, King I, Shattuck AL, Evans I, Satia-Abouta J, Littman AJ, Potter JD. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol. 2004;159: 83-93. doi:10.1093/aje/kwh010
4. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000; 57: 1221-1227. PMid:10902065
5. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008; 154: 1691-1700. doi:10.1038/bjp.2008.210
6. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002; 34: 234-238. doi:10.1086/324351
7. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003; 1619: 243-253. 10.1016/S0304-4165(02)00483-X
8. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002; 71: 1579-1589. doi:10.1016/S0024-3205(02)01913-6
9. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001; 4: 176-184. PMid:11466175
10. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr. 2006; 136 (3 Suppl): 806S-809S. PMid:16484569
11. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais S M. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther. 2004; 309: 303-309. doi:10.1124/jpet.103.061713
12. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2003; 55: 199-202. doi:10.1046/j.1365-2125.2003.01736.x
13. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther. 2003; 74: 170-177. doi:10.1016/S0009-9236(03)00148-6
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005; 22: 525-539. doi:10.2165/00002512-200522060-00006
15. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000; 293: 453-459. PMid:10773015
16. Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH Jr, Piergies A, Karim A. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000; 28: 308-314. PMid:10681375
17. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000; 38: 225-242. doi:10.2165/00003088-200038030-00003
18. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M. Characterization of human cytochrome P450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos. 2007; 35: 1730-1732. doi:10.1124/dmd.107.016758
19. Sautou V, Chopineau J, Terrisse MP, Bastide P. Solid-phase extraction of midazolam and two of its metabolites from plasma for high-performance liquid chromatographic analysis. J Chromatogr. 1991; 571: 298-304. doi:10.1016/0378-4347(91)80459-P
20. Ma F, Lau CE. Determination of midazolam and its metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. J Chromatogr B Biomed Appl. 1996; 682: 109-113. doi:10.1016/0378-4347(96)00069-2
21. Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci. 2006; 95: 2767-2777. doi:10.1002/jps.20743